Herceptin and Intervertebral disc space narrowing - a phase IV clinical study of FDA data

Summary:

Intervertebral disc space narrowing is reported as a side effect among people who take Herceptin (trastuzumab), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Zometa, and have Metastases to bone.

The phase IV clinical study analyzes which people have Intervertebral disc space narrowing when taking Herceptin. It is created by eHealthMe based on reports of 41,859 people who have side effects when taking Herceptin from the FDA, and is updated regularly.

What is Herceptin?

Herceptin has active ingredients of trastuzumab. It is often used in breast cancer. eHealthMe is studying from 42,205 Herceptin users. Check the latest studies of Herceptin.

What is Intervertebral disc space narrowing?

Intervertebral disc space narrowing (spinal disc space narrowing) is found to be associated with 452 drugs and 316 conditions by eHealthMe. Check the latest studies of Intervertebral disc space narrowing.

On Aug, 12, 2026

41,859 people reported to have side effects when taking Herceptin.
Among them, 19 people (0.05%) have Intervertebral disc space narrowing.

Could Herceptin cause Intervertebral disc space narrowing?

Among these 19 people:

How long have people been on Herceptin when they have Intervertebral disc space narrowing? *

What is the gender of people who have Intervertebral disc space narrowing when taking Herceptin? *

female: 73.68 %
male: 26.32 %

What is the age of people who have Intervertebral disc space narrowing when taking Herceptin? *

What are other drugs people take besides Herceptin? *

What are other side effects people have besides Intervertebral disc space narrowing? *

Osteonecrosis Of Jaw (death of bone of jaw): 19 people, 100.00%
Metastases To Bone (cancer spreads to bone): 18 people, 94.74%
Pain: 17 people, 89.47%
Anaemia (lack of blood): 16 people, 84.21%
Atelectasis (partial or complete collapse of the lung): 16 people, 84.21%
Metastases To Central Nervous System (cancer spreads to central nervous system): 16 people, 84.21%
Injury: 15 people, 78.95%
Stress And Anxiety: 15 people, 78.95%
Pleural Effusion (water on the lungs): 14 people, 73.68%
Tricuspid Valve Incompetence (inefficient heart valve): 14 people, 73.68%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 3 people, 15.79%
Sleep Disorder: 1 person, 5.26%
Birth Control: 1 person, 5.26%
Bone Loss: 1 person, 5.26%
Chronic Renal Failure (kidney failure): 1 person, 5.26%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 5.26%
Hypercalcaemia Of Malignancy (elevated calcium (ca+) level in the blood with cancer): 1 person, 5.26%
Impaired Gastric Emptying: 1 person, 5.26%
Insomnia (sleeplessness): 1 person, 5.26%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Herceptin and have Intervertebral disc space narrowing?

- Check whether Intervertebral disc space narrowing is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Herceptin:

Herceptin (42,205 reports)

Browse all side effects of Herceptin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Intervertebral disc space narrowing:

Intervertebral disc space narrowing (452 drugs)

Browse all the conditions that are associated with Intervertebral disc space narrowing:

Intervertebral disc space narrowing (316 conditions)

Related publications that referenced our studies

Saleh M, Bourcier T, Noel G, Speeg-Schatz C, Gaucher D, "Bilateral macular ischemia and severe visual loss following trastuzumab therapy", Acta Oncologica, 2011 Apr .
Saleh M, Bourcier T, Noel G, Speeg-Schatz C, Gaucher D, "Bilateral macular ischemia and severe visual loss following trastuzumab therapy", Acta Oncologica, 2011 Apr .

How the study uses the data?

The study uses data from the FDA. It is based on trastuzumab (the active ingredients of Herceptin) and Herceptin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.